SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2024 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?


To: technetium who wrote (71)5/13/2024 12:07:21 PM
From: technetium  Respond to of 194
 
GLYC Phase III trial results for Uproleselan in AML

finance.yahoo.com
  • Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population

  • Adverse events were consistent with known side effect profiles of chemotherapy used in the study

  • Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting

  • National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing
In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.

Patients treated with uproleselan had a median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the study.

"While the outcome of our Phase 3 study in R/R AML is not what we hoped, we wish to thank the investigators, the participating patients and their families for their dedication to this large, well-controlled randomized study," said Harout Semerjian, Chief Executive Officer of GlycoMimetics. "We are thoroughly analyzing the data in collaboration with medical, statistical and regulatory experts and are committed to submitting a comprehensive data analysis for presentation at an upcoming medical meeting."



To: technetium who wrote (71)5/20/2024 10:11:27 AM
From: technetium1 Recommendation

Recommended By
BulbaMan

  Read Replies (1) | Respond to of 194
 
A decent week all around, more gainers than losers. In fact ten portfolios made a profit for the week, and there are eleven in the black YTD. The NASDAQ composite outperformed (+3.3%) both of the biotech indices (+1.3% and +1.1%).

NVAX continued to soar, up another 86% of its starting value for the week, building on the previous week’s enthusiasm for the $500M infusion, pushing them into third place YTD, +170%. In second, HROW announced Q1 financials touting a big jump in earnings (though still turning in a loss). The release of SCYX’s finances COB Thursday before last may have had something to with its +32% this week., It’s a little more tenuous say that NVCR’s +37% was in response to a release of their quarterly report on the previous week's Monday. LIFE had at least a press release of positive results from interim data of a Phase III trial to make a +22% gain.

On the losing side, profit sharing (?) might apply to VKTX’s drop -36% of the original price, but it was at such stratospheric levels it still has a YTD return of +280% remaining in the top spot for that ranking. CRIS presented a data update on a Phase III trial on Tuesday after the close, with more extensive reporting to come. I’m not sure what in the very sparse report that would result in CRIS dropping -31% for the week, third worst stock. The fourth worst was AKYA (-29%), whose Q1 financials showed a loss for the quarter, and delayed earnings growth. And in fifth, SLDB (-24%) also posted Q1 earnings but no particular news otherwise.

As stated at the beginning it was a net gain for ten portfolios this week. The average portfolio earned $1.9k for the week.

You might think it no surprise that the best portfolio for the week, earning +$17k, was TOMATO, the only one with a position in NVAX. But they actually earned more from a 20% bet on HROW, That sizable gain moved them up four places in the YTD winners list, from eighth to fourth with YTD return of +$25k. Second place JACK HARTMAN (+$6.47k) and third place STEVE LOKNESS (+$6.44K) might be considered a dead heat, separated by a little more than $30 for the week. STEVE LOCKNESS’s return this week moved his portfolio into the black YTD. (+$5.7k). JACK HARTMAN managed a 3 spot improvement to take the sixth place position YTD (+$12.1k).

And at the top ranking YTD returns, BULBAMAN lost -$4.8k, mostly from VKTX, and BLADERUNNER had an OK week in the black, +$1.5k. But the difference was not enough for BLADERUNNER (+$45k YTD) to overtake BULBAMAN (+$69k) in the YTD rankings, it did narrow the gap between the two to $23k. ERIKOTTO had a better week than either of them (number 5, +$4.5k) but stays in third place YTD, $27k, an additional $19k back behind BLADERUNNER.

Report Time Ranges











From

To

















Recent

5/10/24

5/17/2024

















YTD

12/31/2023









Index Portfolios’ Performance









Symbol

Recent P/L

Recent %

YTD P/L

















^IXIC

$3,528.26

3.3%

$11,155.65

















^NBI

$1,254.52

1.3%

$1,427.45

















^SPSIBI

$1,069.36

1.1%

$2,039.65









Share Performance

Recent Performance

YTD Performance



Top Five



Bottom Five



Top Five



Bottom 5

Symbol

P/L / Initial Price

Symbol

P/L / Initial Price

Symbol

YTD P/L / Initial Price

Symbol

YTD P/L/ Initial Price

NVAX

86.0%

VKTX

-35.7%

VKTX

260.0%

AMLX

-87.6%

HROW

46.1%

STTK

-35.1%

JSPR

191.8%

GLYC

-87.3%

SCYX

37.2%

CRIS

-30.7%

NVAX

171.0%

CNSP

-82.9%

NVCR

37.0%

AKYA

-29.0%

CRDF

145.3%

PACB

-79.4%

LIFE

22.0%

SLDB

-23.5%

PYXS

130.6%

RVNC

-65.6%

Average and Median Portfolio Performance



Recent P/L







YTD P/L







Avg.

Median







Avg

Median







$1,891.81

$2,667.75

A. J. MULLEN



$9,790.96

$6,125.13

DEW_DILIGENCE

Top Seven Portfolio Performances

Top Recent Performers

Top YTD Performers

Contestant (Prev. Rank)

Recent P/L

P/L vs. ^SPSIBI

YTD P/L (Rank)

Contestant (Prev. Rank)

YTD P/L

vs. Top Portfolio

P/L vs. ^SPSIBI

Rec. P/L (Rank)

1 - TOMATO (1)

$17,320.94

$16,251.58

$24,964.38 (4)

1 - BULBAMAN (1)

$68,799.02

——

$66,759.38

-$4,791.76 (16)

2 - JACK HARTMANN (5)

$6,469.49

$5,400.14

$12,184.59 (6)

2 - BLADERUNNER (2)

$45,421.21

$23,377.82

$43,381.56

$1,522.88 (10)

3 - STEVE LOKNESS (2)

$6,444.90

$5,375.54

$5,677.78 (10)

3 - ERIKOTTO (3)

$26,634.43

$42,164.59

$24,594.79

$4,484.98 (5)

4 - JR_95 (14)

$6,391.61

$5,322.25

-$12,077.76 (15)

4 - TOMATO (8)

$24,964.38

$43,834.65

$22,924.73

$17,320.94 (1)

5 - ERIKOTTO (13)

$4,484.98

$3,415.62

$26,634.43 (3)

5 - RAJU_BIJLEE (4)

$15,309.89

$53,489.14

$13,270.24

-$2,210.24 (13)

6 - NOTABOT (8)

$3,520.94

$2,451.59

-$5,150.93 (13)

6 - JACK HARTMANN (9)

$12,184.59

$56,614.44

$10,144.94

$6,469.49 (2)

7 - KATHLEEN (6)

$3,148.69

$2,079.33

$5,146.51 (11)

7 - TRACE I11 (6)

$9,758.78

$59,040.24

$7,719.14

-$1,101.67 (12)

8 - ALONER (3)

$2,781.83

$1,712.48

-$5,893.48 (14)

8 - TECHNETIUM (5)

$8,323.68

$60,475.35

$6,284.03

-$4,053.03 (15)

Top Portfolios’ Contents

Top Recent Performance Portfolio (TOMATO)

Top YTD Performance Portfolio (BULBAMAN)

Symbol (Rank)

Initial Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

Symbol (Rank)

Initial Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

BTAI

10.00%

5.6% | -29.8%

-$2,983.05

-$67.80

14.3%

CU6.AX

20.00%

25.4% | 114.2%

$22,832.01

$3,031.94

2.3%

CCCC

10.00%

8.0% | 0.5%

$53.10

-$849.56

9.9%

CYTH

10.00%

5.2% | -11.9%

-$1,194.97

-$440.25

11.4%

HROW

20.00%

23.9% | 49.6%

$9,928.57

$9,214.29

3.3%

LRMR

10.00%

9.6% | 62.2%

$6,219.78

$571.43

6.2%

NVAX

10.00%

21.7% | 171.0%

$17,104.17

$8,604.17

3.7%

PMN

10.00%

9.5% | 60.4%

$6,043.48

-$391.30

6.2%

NVCT

10.00%

5.9% | -26.3%

-$2,625.90

-$299.76

13.6%

SNGX

10.00%

3.1% | -48.3%

-$4,834.21

-$82.89

19.4%

OCUL

10.00%

11.1% | 38.3%

$3,834.08

$1,143.50

7.2%

TCON

10.00%

2.4% | -59.2%

-$5,916.62

-$1,427.76

24.5%

TARA

10.00%

13.2% | 64.8%

$6,479.12

$479.97

6.1%

TLX.AX

15.00%

12.8% | 44.3%

$6,646.33

-$700.97

4.6%

TCON

10.00%

3.3% | -59.2%

-$5,916.62

-$1,427.76

24.5%

VKTX

15.00%

32.0% | 260.0%

$39,003.22

-$5,351.96

1.9%

TERN

10.00%

7.3% | -9.1%

-$909.09

$523.88

11.0%